172 related articles for article (PubMed ID: 8459830)
21. Synthesis of histidine-containing dipeptide affinity-labelling agents. Relative inactivation rates of cathepsins B and L.
Angliker H; Zumbrunn A; Shaw E
Int J Pept Protein Res; 1991 Oct; 38(4):346-9. PubMed ID: 1797709
[TBL] [Abstract][Full Text] [Related]
22. Cruzipain Activates Latent TGF-β from Host Cells during T. cruzi Invasion.
Ferrão PM; d'Avila-Levy CM; Araujo-Jorge TC; Degrave WM; Gonçalves Ada S; Garzoni LR; Lima AP; Feige JJ; Bailly S; Mendonça-Lima L; Waghabi MC
PLoS One; 2015; 10(5):e0124832. PubMed ID: 25938232
[TBL] [Abstract][Full Text] [Related]
23. Antiparasitic effect of a fraction enriched in tight-binding protease inhibitors isolated from the Caribbean coral Plexaura homomalla.
Salas-Sarduy E; Cabrera-Muñoz A; Cauerhff A; González-González Y; Trejo SA; Chidichimo A; Chávez-Planes Mde L; Cazzulo JJ
Exp Parasitol; 2013 Nov; 135(3):611-22. PubMed ID: 24090569
[TBL] [Abstract][Full Text] [Related]
24. Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo.
Wasilewski MM; Lim KC; Phillips J; McKerrow JH
Mol Biochem Parasitol; 1996 Oct; 81(2):179-89. PubMed ID: 8898333
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain.
Roush WR; González FV; McKerrow JH; Hansell E
Bioorg Med Chem Lett; 1998 Oct; 8(19):2809-12. PubMed ID: 9873627
[TBL] [Abstract][Full Text] [Related]
26. The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B.
Crawford C; Mason RW; Wikstrom P; Shaw E
Biochem J; 1988 Aug; 253(3):751-8. PubMed ID: 2845932
[TBL] [Abstract][Full Text] [Related]
27. Subsite specificity of trypanosomal cathepsin L-like cysteine proteases. Probing the S2 pocket with phenylalanine-derived amino acids.
Lecaille F; Authié E; Moreau T; Serveau C; Gauthier F; Lalmanach G
Eur J Biochem; 2001 May; 268(9):2733-41. PubMed ID: 11322895
[TBL] [Abstract][Full Text] [Related]
28. Characterization and expression of proteases during Trypanosoma cruzi metacyclogenesis.
Bonaldo MC; d'Escoffier LN; Salles JM; Goldenberg S
Exp Parasitol; 1991 Jul; 73(1):44-51. PubMed ID: 2055300
[TBL] [Abstract][Full Text] [Related]
29. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
Engel JC; Doyle PS; Palmer J; Hsieh I; Bainton DF; McKerrow JH
J Cell Sci; 1998 Mar; 111 ( Pt 5)():597-606. PubMed ID: 9454733
[TBL] [Abstract][Full Text] [Related]
30. Effects of a marine serine protease inhibitor on viability and morphology of Trypanosoma cruzi, the agent of Chagas disease.
de Almeida Nogueira NP; Morgado-Díaz JA; Menna-Barreto RF; Paes MC; da Silva-López RE
Acta Trop; 2013 Oct; 128(1):27-35. PubMed ID: 23770204
[TBL] [Abstract][Full Text] [Related]
31. A new cruzipain-mediated pathway of human cell invasion by Trypanosoma cruzi requires trypomastigote membranes.
Aparicio IM; Scharfstein J; Lima AP
Infect Immun; 2004 Oct; 72(10):5892-902. PubMed ID: 15385491
[TBL] [Abstract][Full Text] [Related]
32. Trypanosoma cruzi: in vitro activity of Epoxy-alpha-Lap, a derivative of alpha-lapachone, on trypomastigote and amastigote forms.
Bourguignon SC; Castro HC; Santos DO; Alves CR; Ferreira VF; Gama IL; Silva FC; Seguins WS; Pinho RT
Exp Parasitol; 2009 Jun; 122(2):91-6. PubMed ID: 19285074
[TBL] [Abstract][Full Text] [Related]
33. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.
Neitz RJ; Bryant C; Chen S; Gut J; Hugo Caselli E; Ponce S; Chowdhury S; Xu H; Arkin MR; Ellman JA; Renslo AR
Bioorg Med Chem Lett; 2015 Nov; 25(21):4834-4837. PubMed ID: 26144347
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis.
Tomas AM; Miles MA; Kelly JM
Eur J Biochem; 1997 Mar; 244(2):596-603. PubMed ID: 9119029
[TBL] [Abstract][Full Text] [Related]
35. CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells.
Montaser M; Lalmanach G; Mach L
Biol Chem; 2002; 383(7-8):1305-8. PubMed ID: 12437121
[TBL] [Abstract][Full Text] [Related]
36. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease.
Jose Cazzulo J; Stoka V; Turk V
Curr Pharm Des; 2001 Aug; 7(12):1143-56. PubMed ID: 11472258
[TBL] [Abstract][Full Text] [Related]
37. Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents.
Lotem J; Sachs L
Proc Natl Acad Sci U S A; 1996 Oct; 93(22):12507-12. PubMed ID: 8901612
[TBL] [Abstract][Full Text] [Related]
38. Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity.
Aguilera E; Varela J; Birriel E; Serna E; Torres S; Yaluff G; de Bilbao NV; Aguirre-López B; Cabrera N; Díaz Mazariegos S; de Gómez-Puyou MT; Gómez-Puyou A; Pérez-Montfort R; Minini L; Merlino A; Cerecetto H; González M; Alvarez G
ChemMedChem; 2016 Jun; 11(12):1328-38. PubMed ID: 26492824
[TBL] [Abstract][Full Text] [Related]
39. Cathepsin-dependent apoptosis triggered by supraoptimal activation of T lymphocytes: a possible mechanism of high dose tolerance.
Michallet MC; Saltel F; Flacher M; Revillard JP; Genestier L
J Immunol; 2004 May; 172(9):5405-14. PubMed ID: 15100281
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of calpain by peptidyl fluoromethyl ketones.
Angliker H; Anagli J; Shaw E
J Med Chem; 1992 Jan; 35(2):216-20. PubMed ID: 1732539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
